Alle Storys
Folgen
Keine Story von SYGNIS AG mehr verpassen.

SYGNIS AG

euro adhoc: Sygnis Pharma AG
Fusion/Übernahme/Beteiligung
SYGNIS announces agreement on acquisition of Amnestix Inc., USA by partially using the authorized capital

  Ad-hoc-Mitteilung übermittelt durch euro adhoc mit dem Ziel einer
  europaweiten Verbreitung. Für den Inhalt ist der Emittent verantwortlich.
Unternehmen
08.06.2008
Heidelberg, June 8, 2008 - Today, after approval of the supervisory 
board, SYGNIS Pharma AG signed a contract according to which SYGNIS 
Pharma AG shall acquire all shares of Amnestix Inc., a 
privately-owned US biopharmaceutical company located at Burlingame, 
CA. With the acquisition of Amnestix Inc., SYGNIS extends its 
portfolio of compounds relating to the central nervous system (CNS) 
and secures IP-rights of compound-candidates for the treatment of 
CNS-disorders. In addition, SYGNIS gains access to a broad range of 
CNS projects within the Translational Genomics Research Institute in 
Phoenix, Arizona, a world-renowned research-institute in the field of
neurogenomics. Amnestix was founded by scientists from Translational 
Genomics Research Institute in 2006 to develop novel therapeutics and
molecular diagnostics technologies for improving cognition and 
memory. The founders of Amnestix Inc. have discovered a series of 
novel patentable genes and pathways that play a fundamental role in 
memory performance in humans. Amnestix´ Chief Executive Officer, Dr. 
Karoly Nikolich, will remain with Amnestix Inc. in this function. 
SYGNIS will pay approximately EUR4 million in cash and in 
SYGNIS-shares for all shares of Amnestix Inc. Therefore, the 
management and supervisory board of SYGNIS Pharma AG resolved today 
to issue 885.966 new common bearer SYGNIS-shares to the shareholders 
of Amnestix Inc. for the contribution in kind with the exclusion of 
the preemptive rights of SYGNIS shareholders. The current company´s 
capital stock will be increased by approximately 3,2%.
For further information please contact:
Dr. Franz-Werner Haas
VP Operations / General Counsel
Tel: +49 (0) 6221-454 812
Email:  franz-werner.haas@sygnis.de

Rückfragehinweis:

Dr. Franz-Werner Haas
VP Operations / General Counsel
Tel: +49 (0) 179 212 33 95
Email: franz-werner.haas@sygnis.de

Branche: Biotechnologie
ISIN: DE0005043509
WKN: 504350
Index: CDAX
Börsen: Börse Frankfurt / Regulierter Markt/Prime Standard
Börse Berlin / Freiverkehr
Börse Hamburg / Freiverkehr
Börse Stuttgart / Freiverkehr
Börse Düsseldorf / Freiverkehr
Börse Hannover / Freiverkehr
Börse München / Freiverkehr

Weitere Storys: SYGNIS AG
Weitere Storys: SYGNIS AG